Carlsmed (CARL) closed at $14.71 on November 10, 2026, down 8.3% from the previous close, on volume of 107,798 shares (30-day average 85,627).
Data as of November 10, 2026.
Carlsmed’s Strong Execution and Growth Outlook Drive Price Target Increase to $26
TipRanks (Wed, 11-Nov 5:27 AM ET)
Carlsmed, Inc. Non-GAAP EPS of -$0.34 beats by $0.05, revenue of $21.6M beats by $2.44M
Seeking Alpha News (Tue, 10-Nov 4:24 PM ET)
Carlsmed Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Globe Newswire (Tue, 10-Nov 4:01 PM ET)
Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
Globe Newswire (Tue, 27-Oct 4:30 PM ET)
Carlsmed Launches aprevo Lumbar Bi-lateral Posterior System
Globe Newswire (Wed, 14-Oct 9:00 AM ET)
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:01 PM ET)
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
Globe Newswire (Thu, 1-Oct 9:00 AM ET)
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Globe Newswire (Mon, 28-Sep 8:30 AM ET)
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
Globe Newswire (Tue, 15-Sep 7:00 PM ET)
Carlsmed, Inc. Announces Chief Operating Officer Appointment
Globe Newswire (Tue, 8-Sep 4:05 PM ET)
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
Carlsmed trades on the NASDAQ stock market under the symbol CARL.
As of November 10, 2026, CARL stock price declined to $14.71 with 107,798 million shares trading.
CARL has a beta of 2.08, meaning it tends to be more sensitive to market movements. CARL has a correlation of 0.13 to the broad based SPY ETF.
CARL has a market cap of $401.62 million. This is considered a Small Cap stock.
Last quarter Carlsmed reported $19 million in Revenue and -$.39 earnings per share. This beat revenue expectation by $864,816 and missed earnings estimates by -$.01.
The top ETF exchange traded funds that CARL belongs to (by Net Assets): IWM, VTI, VXF, IWO, VTWO.
CARL has outperformed the market in the last year with a return of +16.7%, while the SPY ETF gained +11.2%. In the last 3 month period, CARL beat the market returning +7.1%, while SPY returned -2.7%. However, in the most recent 2 weeks CARL has underperformed the stock market by returning -4.6%, while SPY returned -2.6%.
CARL support price is $15.18 and resistance is $16.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CARL shares will trade within this expected range on the day.
